mDR Ltd has filed an updated Schedule 13G/A with the SEC, revealing that it now holds approximately 9.984% of CytoMed Therapeutics Ltd. This increase in ownership reflects mDR's ongoing strategy to strengthen its position in the pharmaceutical preparations industry.
mDR Ltd, incorporated in Singapore, is known for its investments and operations in various sectors. The company has been actively involved in acquiring shares of CytoMed Therapeutics Ltd, a company focused on pharmaceutical preparations.
According to the recent filing, mDR's beneficial ownership now amounts to 1,191,523 ordinary shares of CytoMed, which were acquired through a combination of direct purchases and a convertible loan agreement. The filing states, "This total is based on (i) 747,414 Ordinary Shares acquired by mDR Limited through subscription of the Issuer's Ordinary Shares between 2021 and 2022 for total consideration of approximately $1,185,449; (ii) 589,509 Ordinary Shares pursuant to the conversion in April 2023 of convertible loan..."
This significant stake could potentially impact mDR's influence over CytoMed's strategic decisions and direction. The filing indicates that mDR has exercised sole voting and dispositive power over these shares, which may allow it to play a more active role in the company's governance.
Details regarding future actions or plans following this filing were not disclosed. Investors and industry analysts will be monitoring mDR's next moves, particularly how it leverages this increased stake in CytoMed and its implications for the broader pharmaceutical preparations sector.